Relation of Ultrasound Findings and Abdominal Symptoms obtained with the CFAbd-Score in Cystic Fibrosis Patients
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/s41598-017-17302-4.pdf
Reference36 articles.
1. Kelly, T. & Buxbaum, J. Gastrointestinal Manifestations of Cystic Fibrosis. Digestive diseases and sciences 60, 1903–1913, https://doi.org/10.1007/s10620-015-3546-7 (2015).
2. Steinkamp, G. & Wiedemann, B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 57, 596–601 (2002).
3. Liong, S. Y., Awad, D., Jones, A. M. & Sukumar, S. A. The adult cystic fibrosis patient with abdominal pain: what the radiologist needs to know. Clinical radiology 66, 132–139, https://doi.org/10.1016/j.crad.2010.09.002 (2011).
4. Tabori, H. et al. Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings. PloS one 12, e0174463, https://doi.org/10.1371/journal.pone.0174463 (2017).
5. Maconi, G., Bianchi Porro G (eds.). Ultrasound of the Gastrointestinal Tract., (Springer-Verlag, 2013).
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Scoring Abdominal Symptoms in People with Cystic Fibrosis;Journal of Clinical Medicine;2024-03-13
2. Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire;Frontiers in Pharmacology;2023-10-25
3. Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER study;Journal of Cystic Fibrosis;2023-10
4. Dynamics of abdominal symptoms during the start of a new therapy with Elexacaftor/Tezacaftor/Ivacaftor using the novel CFAbd-day2day questionnaire;2023-08-02
5. Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER study;2023-07-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3